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Abstract
Background aims. The selection of medium and associated reagents for human mesenchymal stromal cell (hMSC) culture
forms an integral part of manufacturing process development and must be suitable for multiple process scales and expan-
sion technologies. Methods. In this work, we have expanded BM-hMSCs in fetal bovine serum (FBS)- and human platelet
lysate (HPL)-containing media in both a monolayer and a suspension-based microcarrier process. Results. The introduc-
tion of HPL into the monolayer process increased the BM-hMSC growth rate at the first experimental passage by 0.049
day and 0.127/day for the two BM-hMSC donors compared with the FBS-based monolayer process.This increase in growth
rate in HPL-containing medium was associated with an increase in the inter-donor consistency, with an inter-donor range
of 0.406 cumulative population doublings after 18 days compared with 2.013 in FBS-containing medium. Identity and quality
characteristics of the BM-hMSCs are also comparable between conditions in terms of colony-forming potential, osteo-
genic potential and expression of key genes during monolayer and post-harvest from microcarrier expansion. BM-hMSCs
cultured on microcarriers in HPL-containing medium demonstrated a reduction in the initial lag phase for both BM-
hMSC donors and an increased BM-hMSC yield after 6 days of culture to 1.20 ± 0.17 × 105 and 1.02 ± 0.005 × 105 cells/
mL compared with 0.79 ± 0.05 × 105 and 0.36 ± 0.04 × 105 cells/mL in FBS-containing medium. Conclusions. This study
has demonstrated that HPL, compared with FBS-containing medium, delivers increased growth and comparability across
two BM-hMSC donors between monolayer and microcarrier culture, which will have key implications for process transfer
during scale-up.
KeyWords: bioprocess, cell-based therapy, comparability, harvest, human platelet lysate, manufacture, mesenchymal stromal cell,
microcarrier expansion, process development, process transfer
Introduction
The growing field of regenerative medicine (RM) aims
to treat unmet clinical indications such as cardiovas-
cular disease and neurological disorders by restoring
or maintaining cell or tissue function. Cell-based thera-
pies form a large part of this RM industry and have
the potential to transform health care. Human mes-
enchymal stromal cells (hMSCs) are of particular
interest with clinical trials currently underway for mul-
tiple indications [1]. For the majority of these clinical
indications, however, the in vitro expansion of cells is
required to deliver an effective therapeutic dose without
impacting the quality of the cell. Understanding and
defining the quality attributes of hMSC therapies will
be critical for their successful manufacture. This is
proving difficult, however, because of their complex,
multifaceted and poorly understood in vivo mecha-
nisms of action [2].
At present, the majority of hMSC expansion takes
place in static monolayers (T-flasks or multilayer flasks),
which are suitable for the manufacture of the cell
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numbers required for early clinical development.
However, it is widely recognized that these manual pro-
cesses will not be sufficient to cost-effectively meet the
needs for large-scale commercial production, where
lot sizes will likely be on the order of trillions of cells
[3]. For processes to drive toward the production of
cost-effective therapies, they should be scalable, com-
pliant with Good Manufacturing Practices and
amenable to closed and automated process steps.
Microcarriers have been used to culture adher-
ent cells such as BM-hMSCs in suspension in stirred
bioreactors [4], allowing for process scale-up in which
online monitoring and control systems can be used
to deliver consistent and cost-effective BM-hMSC
products [5]. Stirred tank bioreactors are currently em-
ployed for mammalian cell culture in biopharmaceutical
production, and therefore their design and opera-
tion are well understood [6], with the potential to meet
the expected manufacturing demands of large-scale
BM-hMSC therapies. However, considerable work is
required to demonstrate a satisfactory level of com-
parability between the traditional monolayer processes
and these suspension-based systems in terms of cel-
lular growth and quality.
A key aspect of these manufacturing processes is
the culture medium in which the cells are to be
expanded, which is typically supplemented with fetal
bovine serum (FBS) [7]. In addition to lot-to-lot
variability, there are further process constraints on
the use of FBS, such as limited supply, spiraling
costs [8], potential for pathogen transmission and
immunological reactions against bovine antigens [9].
Human platelet lysate (HPL) has been proposed as
a viable alternative in which blood platelets are lysed
to release growth factors such as platelet-derived
growth factor (PDGF), epidermal growth factor
(EGF), transforming growth factor-β (TGF-β) and
fibroblast growth factor (FGF), which then supple-
ment the BM-hMSC growth medium [10].This can
be used as a patient specific supplement from their
own blood plasma or pooled from multiple donors—
for example, Stemulate manufactured by Cook
Regentec. Furthermore, HPL has already been re-
ported as a superior substitute to FBS for the in
vitro expansion of BM-hMSCs [11] and has been
shown to maintain the key cell characteristics and
multipotent capacity [12]. Despite this, little work
has been done to demonstrate the amenability of
HPL to a scalable BM-hMSC manufacturing process,
such as microcarrier suspension culture in stirred
tank bioreactors.
Therefore, the aim of this study was to compare
the relative performance of HPL to FBS for the mono-
layer expansion of BM-hMSCs and the amenability
of HPL to transfer to a microcarrier-based suspen-
sion culture.
Methods
Monolayer culture
Human MSCs were isolated from bone-marrow as-
pirate purchased from Lonza obtained from two healthy
donors with informed consent: BM-hMSC 1 (lot
071313B) and BM-hMSC 2 (lot 071281D).These two
BM-hMSC donors were selected after pre-screening
of five potential donors because of their differing
growth and characteristics [13], representing the two
extremes in terms of culture performance (±5.2 pop-
ulation doublings over 30 days of expansion).The local
ethics committee approved the use of the samples for
research. Cells from passage 1 were cryopreserved at
a density of 1–2 × 106 cells/mL in a freeze medium con-
taining 90% (v/v) FBS (Hyclone) and 10% (v/v)
dimethylsulphoxide (Sigma-Aldrich). Cells were grown
in T-flasks seeded at 5000 cells/cm2 at 37°C in hu-
midified air containing 5% CO2. Dulbecco’s Modified
Eagles Medium (1 g/L glucose; Lonza) supple-
mented with 10% (v/v) FBS (Hyclone) or 10% (v/v)
non-heparin requiring (PL-NH) Stemulate (Cook
Regentec) and 2 mmol/mL UltraGlutamine (Lonza)
was exchanged every 3 days.The FBS batch used in
this study was selected from a number of tested FBS
batches for its favorable growth performance, while
retaining key BM-hMSC characteristics. On passage,
the BM-hMSCs were washed with phosphate-buffered
saline (PBS) without Ca+ or Mg+ and incubated for
4 min with trypsin (0.25%)/ethylenediaminetetraacetic
acid (EDTA; Lonza) for FBS-based culture orTrypLE
Express (Invitrogen) for PL-NH Stemulate-based
culture. Dissociation reagents were inactivated by the
addition of appropriate growth medium, and the cell
suspension was centrifuged at 220g for 5 min.The su-
pernatant was discarded and the remaining pellet was
re-suspended in an appropriate volume of culture
medium. For PL-NH Stemulate culture, BM-hMSCs
underwent one adaptation passage in medium con-
taining 10% (v/v) PL-NH Stemulate. Data represents
four experimental repeats for each condition.
Spinner flask culture
The glass surfaces of 100-mL spinner flasks (diameter
T = 60 mm;BellCo) with amagnetic, horizontal stirrer
bar and a vertical paddle (diameter D = 50 mm) were
siliconized with Sigmacoat (Sigma-Aldrich) according
to the manufacturers’ instructions. Solid, non-porous
Plastic P-102L microcarriers (Solohill) at 500 cm2/
100 mL were prepared following the manufacturer’s
instructions.Microcarrierswerepreconditioned in50 mL
FBS or PL-NHStemulate-containing growthmedium
for 1 h before BM-hMSC inoculation at 6000 cells/
cm2 and cultured in 100 mL of FBS-containing or PL-
NHStemulate-containingmediumat37°C inhumidified
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air containing 5% CO2.A 50%medium exchange was
performed every 3 days. After inoculation, the culture
was static for 1 h, after which the culture was agitated
constantly at the minimum rate for suspension (NJS)
found, experimentally, to be 30 rpm,with dailymedium
samples of 1 mL taken for analysis.Data represent four
experimental repeats for each condition.
Analytical techniques
Measurement of glucose, lactate and ammonia con-
centration in spent medium was performed using a
Cedex Bio-HT (Roche, Germany). Cell counting,
mean cell diameter and viability (via acridine orange
uptake and DAPI exclusion) was performed using a
NucleoCounter NC-3000 automated mammalian cell
counter (Chemometec).Microcarrier-based cell counts
were obtained while the cells were still attached to
microcarriers.The following parameters were obtained:
1. Specific growth rate:
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where qmet is the net specific metabolite consump-
tion or production rate, μ is the specific growth rate
(h−1), Cx(0) is the cell number at the end of the ex-
ponential growth phase, Cmet(t) and Cmet(0) are the
metabolite concentrations at the end and start of the
exponential growth phase, respectively, and t is time
(h).
Microcarrier harvest
Human MSCs were harvested using a method that
we developed previously [14,15]. Briefly, culture
medium was removed from the spinner flask, and cells
were washed twice with 100 mL Ca2+- and Mg2+-
free PBS and dissociated with 50 mL of TrypLE
Express (Stemulate culture) or trypsin (0.25%, w/v)/
EDTA (FBS culture). After cell detachment from the
microcarriers using a short period of high agitation
at 5 × NJS (150 rpm), BM-hMSCs were separated from
microcarriers using a 60-μm Steriflip filter (Millipore).
The cell suspension was then centrifuged and re-
suspended in the appropriate culture medium.
Quantitative osteogenesis assay
Osteogenesis was quantified by BM-hMSC collagen
production using the Sircol Assay (Biocolour) follow-
ing osteogenic differentiation. Collagen standards of
acid-soluble collagenType I at 0, 0.1, 0.2 and 0.4 g/L
were used to quantify collagen production. BM-
hMSCs were seeded at 10 000 cells/cm2 in a well plate
with the previously described cell culture medium; after
3 days, culture growth medium was exchanged to os-
teogenic medium (Irvine Scientific) and cultured for
9 days with a medium exchange taking place every 3
days. To quantify the collagen production cells were
fixed with a solution of 5% acetic acid (v/v) (Sigma)
and 9% formaldehyde (v/v) (Sigma) for 30 min at room
temperature. The monolayer was washed and Sircol
Dye Reagent (Biocolour) was added to each well for
30 min, removed and the cell monolayer was washed
with Acid-Salt Wash Reagent (Biocolour). Alkali
Reagent (Biocolour) was added to each well to release
the collagen-bound Sircol Dye Reagent, and the re-
sulting solution along with the collagen standard was
quantified on a microplate reader (BMG Labtech) at
an absorbance of 555 nm [13].
Colony-forming unit fibroblast efficiency
To assess the colony-forming unit fibroblast efficien-
cy, BM-hMSCs were seeded in a T-flask at 10 cells/
cm2 and cultured with a medium exchange every 3–5
days. After 14-day culture, cells were washed with PBS
and fixed in 4% formaldehyde (v/v) (Sigma) for
30 min. Colonies were stained with 1% crystal violet
(Sigma) in 100% methanol (w/v) for 30 min. Stained
colonies that were made up of more than 25 cells were
recorded as colony-forming units [13,16].
RNA isolation
Cells were harvested for RNA isolation at the begin-
ning, middle and at the end of the expansion process.
Total RNA was collected using TriFast Reagent
(Peqlab) according to the manufacturer’s instruc-
tions. Potential genomic DNA contamination was
removed by digestion with DNase I (Life Technolo-
gies, Germany) followed by reverse transcription
at 50°C for 60 min using Superscript III (Life
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Technologies) and 250 ng Oligo(dT)18-primer (Life
Technologies).
Quantitative real-time polymerase chain reaction
analysis
Quantitative real-time polymerase chain reaction poly-
merase chain reaction was done with SYBR GreenER
qPCR Supermix Universal (Life Technologies), ad-
ditionally added 1× SybrGreenI (Life Technologies)
and 0.2 μmol/mL primer each on the DNA engine
Opticon2 (Bio-Rad) using these cycling conditions:
Primary denaturation at 95°C for 3 min, followed by
35 cycles: 95°C for 30 s, 60°C for 30 s (36B4, p21,
CCL2, VEGF)/55°C (Oct4) and 72°C for 30 s fol-
lowed by fluorescence measurement. The following
primers for cell markers were used: CCL2 (recruits
monocytes, memoryT cells, and dendritic cells to the
sites of inflammation produced by either tissue injury
or infection, NM_002982.3) (Fw) 5′-CCAAGGGCT
CGCTCA GCC AGATGC-3′, (Re) 5′-CGG AGT
TTG GGTTTG CTT GTC CAGG-3′; p21 (regu-
lates the cell cycle and mediates cellular senescence,
NM_000389.4) (Fw) 5′-CCG CCT GCCTCCTCC
CAA CT-3′, (Re) 5 ′-GAG GCC CGT GAG CGA
TGG AA-3′, OCT4 (pluripotent marker associated
with self-renewal of undifferentiated cells,
NM_002701.4) (Fw) 5′-GAG GAGTCC CAG GAC
ATCAA-3′, (Re) 5′-CAT CGGCCTGTGTATATC
CC-3′ andVEGF (associated with vascularization and
growth of blood vessels, NM_001171623.1) (Fw) 5′-
GGAAGGAGCCTCCCTCAGGGTTTCG -3′, (Re)
5′- GCCGGAGTCTCGCCCTCCGG -3′. Serial di-
lutions of plasmid standards were used as positive
controls and for quantification. Expression was
normalized to the reference gene 36B4 (ribosomal
protein large P0 RPLP0, NM_001002.3) (Fw) 5′-
CTCGCTTCCTGGAGGGTGTCCGC -3′, (Re) 5′-
CTCCACAGACAAGGCCAGGACTCG -3′ [16].
hMSC characterization
Immunophenotype analysis was performed by mul-
tiparameter flow cytometry before and after the BM-
hMSC expansion process using a previously developed
protocol [17]. Short tandem repeat analysis was com-
pleted by LGC Standards (UK) under their cell line
authentication program.Morphology images were ob-
tained using a light microscope (Nikon Eclipse
TS-100).
The BM-hMSC differentiation was induced using
PRIME-XV Differentiation Serum-Free Medium
(Irvine Scientific) according to the manufacturer’s in-
structions.After 21 days the differentiation media were
removed, cells rinsed with PBS then fixed with 4%
(v/v) paraformaldehyde at room temperature.
Adipocytes were stained with 1% (w/v) oil red O
(Sigma-Aldrich) in isopropanol at room tempera-
ture and rinsed with distilled water. Osteoblasts were
incubated with 2.5% (v/v) silver nitrate (Sigma-
Aldrich) under ultraviolet light (30-min exposure),
rinsed with distilled water and stained with fast violet
solution (Sigma-Aldrich) containing 4% (v/v) naph-
thol AS-MX phosphate alkaline (Sigma-Aldrich) for
45 min at room temperature in the dark. Chondrocytes
were stained with 1% (w/v) Alcian blue (Sigma-
Aldrich) in 0.1 mol/L hydrochloric acid (Sigma-
Aldrich). After 30-min incubation, cells were rinsed
three times with 0.1 mol/L HCl. After staining, dif-
ferentiated cells were visualized under a light
microscope (Nikon Eclipse TS-100) [13].
Statistical analysis
Results were deemed to be significant if P < 0.05 using
a two-tailed Student’s t-test assuming unequal
variances.
Results
Monolayer expansion of BM-hMSCs
The successful translation of many BM-hMSC thera-
pies will require processes that enable cell expansion
because the therapeutic dose is likely to exceed the
number of harvested cells. It can be seen from
Figure 1(A,B) that BM-hMSCs expanded in HPL have
significantly higher (P < 0.05) growth rate for both
donors compared with FBS.This is most apparent over
the first three passages (18 days culture) before the
cells expanded in HPL undergo a senescent phase at
approximately 10 cumulative population doublings in
the monolayer expansion process. It can be seen from
Figure 1C that this movement into the senescent phase
is associated with an increase in mean cell diameter
through expansion, which has been reported previ-
ously [13,16] and can potentially be used as a process
metric to indicate the onset of senescence during a
BM-hMSC manufacturing process. It will be impor-
tant to minimize this level of senescence during the
manufacturing process because it is likely to have a
detrimental impact on the quality and quantity of the
final product.This action is particularly important in
the HPL-based process, which encounters this senes-
cent phase much earlier during expansion.
It is important that the BM-hMSCs expanded
during this process also maintain their identity, as
defined by the International Society for Cellular
Therapy minimum criteria. Short tandem repeat anal-
ysis has confirmed the genotype of both BM-hMSC
lines at the end of the expansion process in both con-
ditions (supplementary Figure S1), although previous
studies have demonstrated that changes to BM-
hMSC karyotype does not affect their in vivo
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characteristics [18].Tri-lineage differentiation poten-
tial has also been maintained (supplementary
Figure S2) and immunophenotype has been con-
firmed by multiparameter flow cytometry
(supplementary Figure S3). In addition to BM-
hMSC identity, it is also important to consider the
effect of the expansion process on the quality attri-
butes of the BM-hMSCs because these will be more
relevant to the function of the therapy.
The presence of key BM-hMSC genes through the
expansion process is also important because they are
likely to play a key role in the in vivo function of the
cell. Figure 4 shows the RNA expression of the donor
BM-hMSC lines in FBS- and HPL-containing medium
against population doubling level, with maintained ex-
pression of P21 and CCL2.The CCL2 gene has been
implicated in the recruitment of T cells, monocytes
and dendritic cells to sites of inflammation [36] and
is therefore an important gene of which to retain ex-
pression for clinical indications that require a level of
immune modulation. Figure 4B shows the relative ex-
pression of P21, a gene relating to cellular aging and
senescence, which has not increased significantly
throughout the expansion process in HPL- nor FBS-
based expansion.
Microcarrier expansion of BM-hMSCs
The growth rates of BM-hMSCs will also play a part
in reducing costs because accommodating BM-
hMSCs with a lower expansion potential will reduce
annual production rates [13,19]. Figure 6A shows the
growth rate of the two BM-hMSC donors over 6 days
in culture in both FBS- and HPL-containing media.
The growth rates of the two donor BM-hMSCs in the
HPL-based medium is significantly higher (P < 0.01)
than the FBS-containing medium for both of the BM-
hMSC lines, in particular BM-hMSC 2 showed
extremely low growth rates in FBS with 0.44 ± 0.18
population doublings over the 6-day growth period.
This increase in growth rate for BM-hMSCs during
microcarrier culture has also been demonstrated at
5% HPL compared with 10% FBS [20]. BM-hMSCs
cultured on microcarriers in HPL-containing
medium demonstrated an increased BM-hMSC
yield after 6 days of culture to 1.20 ± 0.17 × 105
Figure 1. Growth rates of the two BM-hMSC lines over 36 days of expansion. Showing (A) cumulative population doublings showing
increased growth rate in HPL (P < 0.05), (B) specific growth rate of hMSCs in FBS and HPL and (C) mean cell diameter throughout
culture. Data shows mean ± SD (n = 4).
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and 1.02 ± 0.005 × 105 cells/mL compared with
0.79 ± 0.05 × 105 and 0.36 ± 0.04 × 105 cells/mL in
FBS-containing medium. Despite the improved yield
in HPL-containing medium, these cell yields still need
to be further increased to produce 1012 BM-hMSCs
per batch and thus to be economical even at the com-
mercial scale. It is also likely that increasing the
functionality of the BM-hMSC product will play a role
in reducing costs, and therefore it will be important
to assess the effect of different culture conditions on
product functionality.
The net metabolite flux of the cells in microcarrier
culture has been measured for BM-hMSC 1 and BM-
hMSC 2. Figure 7A shows the glucose consumption
of BM-hMSCs in FBS and HPL culture, which was
between 11.13 and 15.32 pmol/cell/day with no sig-
nificant difference measured across these conditions.
The lactate production rate is shown in Figure 7B,
which again shows a similar level of production between
FBS and HPL.This suggests that the BM-hMSCs in
both conditions are using similar metabolic path-
ways, as confirmed by the yield of lactate from glucose
(Figure 7D). This is in contrast to previous studies
using serum-free medium, which demonstrated that
BM-hMSCs tend to favor the relative production of
ammonia over lactate during microcarrier culture under
serum-free conditions [21].There was, however, a re-
duction in the production of ammonia for BM-
hMSC 1 in HPL to 1.20 ± 0.03 pmol/cell/day,
suggesting altered amino acid use, which may be related
to the need for precursors (e.g., glutamine and as-
paragine) supporting purine and pyrimidine
biosynthesis [22].
Discussion
Monolayer expansion of BM-hMSCs
Increasing the manufacturing consistency between
donors will be important for increasing the cost-
effectiveness of cell-based therapy processes and will
support further development and future scale-up
[13,16]. It can be seen from Figure 1A that the growth
rates between the two donor BM-hMSCs in HPL are
not only higher but more consistent. This difference
in behavior can be explained in part by the change
in morphology of the BM-hMSCs in HPL (Figure 2),
which is similar for both of the BM-hMSC donors.
In contrast, the same donor cells expanded in FBS-
containing medium have a markedly different
morphology.
Previous studies have highlighted the importance
of minimizing the expansion ratio of BM-hMSCs
because their therapeutic potential decreases as the
number of cumulative population doublings in-
creases [23,24]. Figure 3A shows the effect of the
increasing number of population doublings on the
colony-forming potential of the BM-hMSCs, with a
general decline as the number of population doublings
increases.This decline has been highlighted by others
[25] and will have implications for off-the-shelf manu-
facturing processes requiring a large number of cells.
Declining quality through expansion will result in the
Figure 2. Phase-contrast images of the two BM-hMSC lines showing the increased consistency in morphology between the cell lines under
HPL expansion compared with FBS.
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use of multiple donor samples for the expansion process
to reduce the overall number of population doublings
and maintain product quality. The reduced colony-
forming potential is particularly apparent for HPL-
based culture, which should be further investigated
before process transfer to ensure it is not having a det-
rimental impact on the product quality for a particular
clinical indication, although it may not necessarily be
a relevant marker for all applications.
This trend is also presented in Figure 3B, which
shows that the osteogenic potential of the BM-
hMSCs decreases as the number of population
doublings increases. Such results are further sup-
ported by in vivo clinical data [26] for these indications
as well as for additional indications outside of the BM-
hMSC niche [27]. It is important to assess the impact
of the expansion process on quality attributes early in
development because it will determine the maximum
allowable expansion ratio of the product for each par-
ticular indication, which will in turn influence the
overall cost and scale of the therapy.
Despite the maintenance of CCL2 and P21 during
expansion, the RNA expression of Oct4 and VEGF
has shown a slight decrease with increasing popula-
tion doublings. Oct4 is a marker of pluripotency,mainly
associated with embryonic stem cells, but has previ-
ously shown expression in BM-hMSCs [37] and will
be important for cell-based products that require cel-
lular differentiation. VEGF has been shown to be a
highly important gene in the promotion of angiogen-
esis by BM-hMSCs [38], which will be particularly
important for cardiac repair, a key target for a number
of BM-hMSC-based therapies. Despite a higher rel-
ative expression of VEGF in BM-hMSCs cultured
in HPL compared with FBS, there is a decrease in
its expression as the number of population doublings
increases, which should be further investigated if the
BM-hMSC product requires a high level of cumula-
tive population doublings and is to be used for clinical
indications requiring some level of angiogenesis.
Measuring cell metabolite flux during the expan-
sion process is likely to form the basis of many online
BM-hMSC monitoring systems during manufac-
ture, as it has been for many traditional bioprocesses
[28].The implementation of online monitoring pro-
cesses for BM-hMSC production will allow for control
systems to be put in place, which will be essential to
reduce variation in product attributes and increase
process consistency.The development of these control
systems for BM-hMSCmanufacturing processes is cur-
rently at an early stage, and a better understanding
of the cell must be gained before models can be de-
veloped to simulate the effect of changing metabolite
levels on cellular growth and function. Figure 5 shows
the relative flux of glucose, lactate and ammonium
throughout expansion, which increases as the BM-
hMSCs move toward senescence. This change
highlights the potential value of introducing an online
monitoring system for metabolite flux because in-
creasing cell size and per-cell metabolite flux could
be used as an early indication of this senescence, and
therefore process interventions (such as cell harvest)
could be made to ensure that senescence does not
affect the final product.
Microcarrier expansion of BM-hMSCs
For numerous clinical indications, BM-hMSCs will
need to be manufactured on a large scale (on the order
of 1012 cells per batch) to reduce the cost of produc-
tion and to meet the market need for the treatment.
Microcarriers have previously been demonstrated to
support the proliferation and harvest of BM-hMSCs
in suspension [4,29,30] and therefore have the
Figure 3. Colony-forming efficiency and osteogenic potential of two BM-hMSC lines against number of population doublings through-
out the expansion process. Showing (A) colony-forming efficiency and (B) collagen production under osteogenic conditions demonstrating
the decrease through culture. CFU-f, colony-forming unit fibroblast.
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potential to be operated up to and beyond the
thousand-liter scale.
The increased consistency between donors gives
significant advantages to the manufacturing process
because increased production rates and reduced batch
failure rates are likely to reduce the overall cost of the
product. It can be seen from Figure 6B that the lag
phase experienced by BM-hMSCs in FBS culture
between days 0 and 3 is not present when the cells
are cultured in HPL, which is the likely cause of the
difference in growth rates over the 6-day period.The
reason for this may be due to an increase in the at-
tachment rate of the cells, which in turn shortens the
lag phase prior to cell division taking place.This link
between attachment efficiency and cell growth is well
established [31] and the level of relevant attachment
proteins present in HPL is typically higher than in FBS,
which will contribute to this effect [32].The attach-
ment of the BM-hMSCs to the culture surface is
particularly important for suspension culture, where
the cells and microcarriers are constantly agitated
throughout the culture period.
The post-expansion detachment and separation of
the BM-hMSCs from the microcarriers is of critical
importance for a scalable production process because
cellular attributes must be maintained throughout the
process [14,15].The same harvest protocol adopted
by Nienow et al. [14,15] was modified for this study
by replacing trypsin-EDTA withTrypLE Express for
the HPL culture to ensure the process was animal-
component free.The post-harvest viability from both
donor BM-hMSC lines in FBS and HPL was >95%,
demonstrating that this harvest process did not have
a detrimental impact on the membrane integrity of
the cells. It is important that BM-hMSC character-
istics are also maintained after this detachment and
separation process from the microcarriers. Figure 8
shows the effect of the total microcarrier process on
BM-hMSC attributes compared with pre-expansion
for colony forming efficiency (Figure 8A), osteo-
genic potential (Figure 8B), specific outgrowth rate
(Figure 8C) and mean cell diameter (Figure 8D).The
colony-forming efficiency of the BM-hMSCs follow-
ing the microcarrier expansion and harvest process
generally saw an increase, with a significant increase
for BM-hMSC 1 in HPL (P < 0.05) compared with
pre-expansion. Similarly, the specific outgrowth rate
and mean cell diameter have been maintained
Figure 4. Quantitative real-time polymerase chain reaction analysis showing RNA expression of four hMSC genes for the two BM-hMSC
lines in FBS and HPL expansion. Showing maintained expression of VEGFA (A), P21 (B) and Oct4 (C) and CCL2 (D). cDNA is nor-
malized to housekeeping gene 36B4.
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post-harvest, demonstrating that the microcarrier
process has not affected these BM-hMSC character-
istics. In contrast, the osteogenic potential of the BM-
hMSCs decreased for all conditions (P < 0.01), which
should be further investigated if the BM-hMSCs are
to be used for clinical indications relating to the
production of collagen.There is the potential however,
for this type of clinical indication, that biodegrad-
able microcarriers could be directly implanted as a cell-
scaffold construct to support the regeneration of bone
tissue [33], removing the need for cell harvest
altogether.
Figure 5. Per-cell metabolite flux of two BM-hMSC lines over 36 days of monolayer expansion. Showing (A) increasing per-cell glucose
consumption rate through culture, (B) increasing per cell lactate production rate through culture, (C) increasing per-cell ammonia pro-
duction rate through culture and (D) yield of lactate from glucose through culture. Data are mean ± SD (n = 4).
Figure 6. Growth rates of hMSCs cultured on microcarriers in FBS-containing medium and HPL-containing medium for 6 days showing
increased growth rates in HPL (P < 0.01). (A) Specific growth rate and (B) cumulative population doublings. Data are mean ± SD (n = 4).
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This comparison of performance demonstrates that
HPL is a viable alternative to FBS for the microcarrier
culture of BM-hMSCs and has the potential to be
taken forward to support further process develop-
ment and scale-up.The increased consistency in growth
between donors in HPL will also benefit the devel-
opment of both patient specific and off-the-shelf BM-
hMSC therapies, allowing for increased production
rates and shorter processing times. That said, more
work is required to integrate further quality and func-
tionality assays into the microcarrier process.This is
critical to ensure comparability as the bioprocess is
developed further and scaled-up.
Comparison of monolayer and microcarrier culture for
process transfer
One of the key challenges in the successful develop-
ment of scalable cell therapy manufacturing processes
is in the process transfer away from traditional manual
monolayer techniques. The decision of when in the
development cycle to complete these bridging studies
and move toward a scalable process should be care-
fully considered, and many companies have incurred
spiraling costs as a result of waiting until the end of
clinical development before commercial production
can commence. The advantages of automated and
closed processing systems in driving scalable produc-
tion by reducing costs should not be underestimated
[34,35], with suspension-based systems being a lead
candidate because they are routinely operated in this
manner. This process transfer from monolayer to
microcarrier culture will aim to assess the impact of
the new process on the product attributes to ensure
they are comparable between the processes, avoid-
ing the need to repeat clinical work, which will require
significant time and capital.
Obtaining similar growth rates of the BM-hMSCs
from the monolayer and microcarrier processes is also
important because this will affect the number of BM-
hMSCs that can be manufactured per unit time, which
will reduce the number of batches produced per year.
Table I shows the comparison of the monolayer and
microcarrier process for BM-hMSC 1 and 2 in FBS-
and HPL-based culture. The growth rate of BM-
hMSCs in FBS-based culture showed a significant
reduction from monolayer to microcarrier culture for
both BM-hMSC lines (P < 0.05 and P < 0.01), which
Figure 7. Per-cell metabolite flux of two BM-hMSC lines over 6 days of microcarrier expansion. Showing (A) per-cell glucose consump-
tion rate, (B) per-cell lactate production rate, (C) per-cell ammonia production rate and (D) yield of lactate from glucose. Data are mean ± SD
(n = 4).
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is particularly apparent for BM-hMSC 2, with a re-
duction from 0.14 ± 0.02 to 0.05 ± 0.02 day. This
reduction would create challenges during process scale-
up within a suspension-based system and would
necessitate careful selection of donor material for master
cell banks to ensure it is amenable to this potential
change in process conditions from static to agitated
culture. It is likely that this widening of the gap in
growth rates between the static monolayer process and
agitated microcarrier culture is due to the efficiency
of cell attachment, which becomes more important
within the agitated environment.
In contrast to FBS-based culture, the use of HPL
proved more effective in supporting the transfer of the
process from static to agitated conditions with only a
slight reduction in the growth rate of BM-hMSC 2
and no significant difference between the monolayer
and microcarrier growth rate of BM-hMSC 1. This
consistency demonstrates the potential of HPL to be
used as amedium supplementwithinmonolayer culture
as well as for suspension culture of BM-hMSCs.Table I
also shows that the colony-forming efficiency, mean
cell diameter and outgrowth rate have not been reduced
for the microcarrier process, which will be important
during process transfer and scale-up toward commer-
cial production. It is also evident from Table I that
the yield of lactate from glucose is more similar when
comparingmonolayer andmicrocarrier culture inHPL
with FBS, which suggests a maintenance of the gly-
colytic pathway during microcarrier culture [36]. All
this means that HPL represents a beneficial alterna-
tive to FBS for monolayer expansion processes and
further process transfer into suspension-based systems.
This improvement has implications for both patient-
specific and off-the-shelf BM-hMSC therapies in terms
of increasing yield and reducing costs of therapies that
are currently in development.
The development of serum-free microcarrier ex-
pansion processes will also be important in driving cost-
effective BM-hMSC products [21,37]. However,
serum-free production may not be amenable to every
product because process transfer into suspension
without the use of serum may not support the ex-
pansion of all cell types, with the time and cost
associated with demonstrating process comparabil-
ity for such a substantial process change becoming
prohibitive as the process is scaled [38]. It is impor-
tant that these competing factors are evaluated at an
early stage to avoid unnecessary and costly process
changes during clinical development.
Figure 8. Post-harvest hMSC quality compared with pre-expansion demonstrating retention of key attributes, showing (A) colony-
forming efficiency, (B) osteogenic potential, (C) specific growth rate and (D) mean cell diameter. Data are mean ± SD (n = 4).
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Conclusions
This study has demonstrated that pooled HPL rep-
resents a viable alternative to a pre-selected batch of
FBS for the monolayer and microcarrier culture of BM-
hMSCs. The maintenance of BM-hMSC growth
potential between monolayer and microcarrier expan-
sion in HPL-based medium offers significant
advantages for process transfer during clinical devel-
opment, which will be important for demonstrating
comparability and reducing associated development
costs.
Acknowledgments
This study has been funded by the Engineering
and Physical Sciences Research Council (EPSRC)
(grant no. EP/L015072/1) and FUJIFILM Diosynth
Biotechnologies.
Disclosure of interests:The authors have no com-
mercial, proprietary, or financial interest in the products
or companies described in this article.
References
[1] Heathman TRJ, Nienow AW,McCall MJ, Coopman K, Kara
B, Hewitt CJ. The translation of cell-based therapies: clinical
landscape and manufacturing challenges. Regen Med
2015;10:49–64.
[2] Carmen J, Burger SR, McCaman M, Rowley JA. Developing
assays to address identity, potency, purity and safety: cell
characterization in cell therapy process development. Regen
Med 2012;7:85–100.
[3] Rowley J, Abraham E, Campbell A, Brandwein H, Oh S.
Meeting lot-size challenges of manufacturing adherent cells
for therapy. BioProc Int 2012;10:16–22.
[4] Rafiq QA, Brosnan KM, Coopman K, Nienow AW, Hewitt
CJ. Culture of human mesenchymal stem cells on
microcarriers in a 5 l stirred-tank bioreactor. Biotechnol Lett
2013;35:1233–45.
[5] Simaria AS, Hassan S, Varadaraju H, Rowley J, Warren K,
Vanek P, et al. Allogeneic cell therapy bioprocess economics
and optimization: single-use cell expansion technologies.
Biotechnol Bioeng 2014;111:69–83.
[6] Nienow AW. Reactor engineering in large scale animal cell
culture. Cytotechnology 2006;50:9–33.
[7] Wappler J, Rath B, Laufer T, Heidenreich A, Montzka K.
Eliminating the need of serum testing using low serum culture
conditions for human bone marrow-derived mesenchymal
stromal cell expansion. Biomed Eng Online 2013;12:15.
[8] Brindley DA, Davie NL, Culme-Seymour EJ,Mason C, Smith
DW, Rowley JA. Peak serum: implications of serum supply
for cell therapy manufacturing. Regen Med 2012;7:7–13.
[9] Kocaoemer A, Kern S, Kluter H, Bieback K. Human AB
serum and thrombin-activated platelet-rich plasma are suitable
alternatives to fetal calf serum for the expansion of
mesenchymal stem cells from adipose tissue. Stem Cells
2007;25:1270–8.
[10] Lubkowska A, Dolegowska B, Banfi G. Growth factor content
in PRP and their applicability in medicine. J Biol Regul
Homeost Agents 2012;26:3S–22.
[11] Schallmoser K, Bartmann C, Rohde E, Bork S, Guelly C,
Obenauf AC, et al. Replicative senescence-associated geneT
ab
le
I.
C
om
pa
ri
so
n
of
m
on
ol
ay
er
an
d
m
ic
ro
ca
rr
ie
r
cu
lt
ur
e
of
hM
S
C
s
in
F
B
S
-
an
d
H
P
L
-c
on
ta
in
in
g
m
ed
iu
m
sh
ow
in
g
th
e
im
pr
ov
ed
pr
oc
es
s
tr
an
sf
er
un
de
r
H
P
L
.
G
ro
w
th
ra
te
(d
ay
−1
)
M
ea
n
ce
ll
di
am
et
er
(μ
m
)
C
F
U
ef
fic
ie
nc
y
(%
)
O
st
eo
ge
ni
c
po
te
nt
ia
l
O
ut
gr
ow
th
ra
te
(d
ay
−1
)
Y
ie
ld
of
la
ct
at
e
fr
om
gl
uc
os
e
(m
ol
/m
ol
)
M
L
M
C
M
L
M
C
M
L
M
C
M
L
M
C
M
L
M
C
M
L
M
C
B
M
-h
M
S
C
1
H
P
L
0.
27
±
0.
02
0.
25
±
0.
02
15
.5
3
±
0.
06
15
.4
7
±
0.
38
11
.6
0
±
1.
82
*
15
.3
3
±
0.
61
*
0.
24
±
0.
01
**
0.
18
±
0.
01
**
0.
28
±
0.
05
0.
33
±
0.
01
1.
22
±
0.
10
1.
34
±
0.
14
F
B
S
0.
23
±
0.
02
*
0.
18
±
0.
01
*
16
.3
3
±
0.
22
14
.9
3
±
1.
27
23
.9
0
±
1.
54
26
.6
0
±
0.
85
0.
30
±
0.
02
**
0.
26
±
0.
02
**
0.
21
±
0.
02
*
0.
25
±
0.
01
*
1.
00
±
0.
13
*
1.
63
±
0.
35
*
B
M
-h
M
S
C
2
H
P
L
0.
27
±
0.
01
*
0.
22
±
0.
01
*
16
.1
5
±
0.
25
*
15
.5
3
±
0.
08
*
14
.1
0
±
0.
38
15
.6
0
±
1.
74
0.
30
±
0.
02
**
0.
19
±
0.
01
**
0.
31
±
0.
01
0.
32
±
0.
01
1.
24
±
0.
02
1.
23
±
0.
03
F
B
S
0.
14
±
0.
02
**
0.
05
±
0.
02
**
17
.1
3
±
0.
46
**
15
.2
3
±
0.
46
**
12
.0
0
±
0.
86
18
.4
0
±
3.
02
0.
41
±
0.
03
**
0.
31
±
0.
04
**
0.
16
±
0.
02
*
0.
21
±
0.
01
**
0.
89
±
0.
13
1.
20
±
0.
35
S
ta
ti
st
ic
s
sh
ow
si
gn
ifi
ca
nc
e
be
tw
ee
n
m
on
ol
ay
er
an
d
m
ic
ro
ca
rr
ie
r
co
nd
it
io
n.
C
F
U
,
co
lo
ny
-f
or
m
in
g
un
it
;
M
C
,
m
on
oc
ar
ri
er
;
M
L
,
m
on
ol
ay
er
.
*P
<
0.
05
;
**
P
<
0.
01
.
534 T. R. J. Heathman et al.
expression changes in mesenchymal stromal cells are similar
under different culture conditions. Haematologica
2010;95:867–74.
[12] Doucet C, Ernou I, Zhang Y, Llense JR, Begot L, Holy X,
et al. Platelet lysates promote mesenchymal stem cell
expansion: a safety substitute for animal serum in cell-based
therapy applications. J Cell Physiol 2005;205:228–36.
[13] Heathman TRJ, Rafiq QA, Chan AKC, Coopman K, Nienow
AW, Kara B, et al. Characterization of human mesenchymal
stem cells from multiple donors and the implications for
large scale bioprocess development. Biochem Eng J 2016;
108:14–23.
[14] Nienow AW, Rafiq QA, Coopman K, Hewitt CJ. A potentially
scalable method for the harvesting of hMSCs from
microcarriers. Biochem Eng J 2014;85:79–88.
[15] Nienow AW, Hewitt CJ, Heathman TRJ, Glyn VAM, Fonte
GN, Hanga MP, et al. Agitation conditions for the culture
and detachment of hMSCs from microcarriers in multiple
bioreactor platforms. Biochem Eng J 2016;108:24–9.
[16] Heathman TRJ, Stolzing A, Fabian C, Rafiq QA, Coopman
K, Nienow AW, et al. Serum-free process development:
improving the yield and consistency of human mesenchymal
stromal cell production. Cytotherapy 2015;17:1524–35.
[17] Chan AK, Heathman TR, Coopman K, Hewitt CJ.
Multiparameter flow cytometry for the characterisation of
extracellular markers on human mesenchymal stem cells.
Biotechnol Lett 2014;36:731–41.
[18] Izadpanah R, Kaushal D, Kriedt C, Tsien F, Patel B, Dufour
J, et al. Long-term in vitro expansion alters the biology of adult
mesenchymal stem cells. Cancer Res 2008;68:4229–38.
[19] Naing MW, Gibson DA, Hourd P, Gomez SG, Horton RB,
Segal J, et al. Improving umbilical cord blood processing to
increase total nucleated cell count yield and reduce cord input
wastage by managing the consequences of input variation.
Cytotherapy 2015;17:58–67.
[20] Sunil N, Punreddy S, Niss K, Jing D. Expansion of human
mesenchymal stem cells: using microcarriers and human
platelet lysate. BioProc Int 2014;12:74–8.
[21] Heathman TRJ, Glyn VAM, Picken A, Rafiq QA, Coopman
K, Nienow AW, et al. Expansion, harvest and cryopreservation
of human mesenchymal stem cells in a serum-free microcarrier
process. Biotechnol Bioeng 2015;112:1696–707.
[22] Higuera GA, Schop D, Spitters TW, van Dijkhuizen-Radersma
R, Bracke M, de Bruijn JD, et al. Patterns of amino acid
metabolism by proliferating human mesenchymal stem cells.
Tissue Eng Part A 2012;18:654–64.
[23] Stolzing A, Scutt A. Age-related impairment of mesenchymal
progenitor cell function. Aging Cell 2006;5:213–24.
[24] von Bahr L, Batsis I, Moll G, Hagg M, Szakos A, Sundberg
B, et al. Analysis of tissues following mesenchymal stromal
cell therapy in humans indicates limited long-term engraftment
and no ectopic tissue formation. Stem Cells 2012;30:1575–8.
[25] Jung S, Panchalingam KM, Rosenberg L, Behie LA.
Ex vivo expansion of human mesenchymal stem cells in
defined serum-free media. Stem Cells Int 2012;2012:21.
[26] Yamachika E, Iida S. Bone regeneration from mesenchymal
stem cells (MSCs) and compact bone-derived MSCs as an
animal model. Jpn Dent Sci Rev 2013;49:35–44.
[27] Moll G, Alm JJ, Davies LC, von Bahr L, Heldring N,
Stenbeck-Funke L, et al. Do cryopreserved mesenchymal
stromal cells display impaired immunomodulatory and
therapeutic properties? Stem Cells 2014;32:2430–42.
[28] Kirouac DC, Zandstra PW. The systematic production of cells
for cell therapies. Cell Stem Cell 2008;3:369–81.
[29] dos Santos F, Andrade PZ, Abecasis MM, Gimble JM, Chase
LG, Campbell AM, et al. Toward a clinical-grade expansion
of mesenchymal stem cells from human sources: a
microcarrier-based culture system under xeno-free conditions.
Tissue Eng Part C Methods 2011;17:1201–10.
[30] Chen AK-L, Reuveny S, Oh SKW. Application of human
mesenchymal and pluripotent stem cell microcarrier cultures
in cellular therapy: achievements and future direction.
Biotechnol Adv 2013;31:1032–46.
[31] Mitchell PD, Ratcliffe E, Hourd P, Williams DJ, Thomas RJ.
A quality-by-design approach to risk reduction and
optimization for human embryonic stem cell cryopreservation
processes. Tissue Eng Part C Methods 2014;20:941–50.
[32] Bieback K. Platelet lysate as replacement for fetal bovine serum
in mesenchymal stromal cell cultures. Transfus Med Hemother
2013;40:326–35.
[33] Gao T, Zhang N, Wang Z, Wang Y, Liu Y, Ito Y, et al.
Biodegradable microcarriers of poly(lactide-co-glycolide) and
nano-hydroxyapatite decorated with igf-1 via polydopamine
coating for enhancing cell proliferation and osteogenic
differentiation. Macromol Biosci 2015;15(8):1070–80.
[34] Williams DJ, Thomas RJ, Hourd PC, Chandra A, Ratcliffe
E, Liu Y, et al. Precision manufacturing for clinical-quality
regenerative medicines. PhilosTransact A Math Phys Eng Sci
2012;370:3924–49.
[35] Hampson B. Closed processing for cell therapies: engineering
risk reduction and patient safety during manufacturing. Genet
Eng Biotechnol News 2014;34.
[36] Pattappa G, Heywood HK, de Bruijn JD, Lee DA. The
metabolism of human mesenchymal stem cells during
proliferation and differentiation. J Cell Physiol 2011;226:
2562–70.
[37] Heathman T. Development of a controlled bioreactor process
to drive the consistent manufacture of human mesenchymal
stem cells from multiple donors. Cytotherapy 2015;17:
S81–2.
[38] Archibald PRT, Chandra A, Thomas D,Morley G, Lekishvili
T, Devonshire A, et al. Comparability of scalable, automated
hMSC culture using manual and automated process steps.
Biochem Eng J 2015;doi:10.1016/j.bej.2015.07.001.
Appendix: Supplementary material
Supplementary data to this article can be found online
at doi:10.1016/j.jcyt.2016.01.007.
Monolayer and microcarrier culture of BM-hMSCs in HPL 535
